NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free GTBP Stock Alerts $4.45 +0.08 (+1.83%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.36▼$4.7550-Day Range$3.76▼$7.0552-Week Range$3.52▼$18.00Volume10,831 shsAverage Volume12,996 shsMarket Capitalization$6.14 millionP/E RatioN/ADividend YieldN/APrice Target$105.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GT Biopharma alerts: Email Address GT Biopharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside2,259.6% Upside$105.00 Price TargetShort InterestHealthy0.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($9.31) to ($10.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 stars 3.3 Analyst's Opinion Consensus RatingGT Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $105.00, GT Biopharma has a forecasted upside of 2,259.6% from its current price of $4.45.Amount of Analyst CoverageGT Biopharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.40% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently decreased by 14.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GTBP. Previous Next 3.9 News and Social Media Coverage News SentimentGT Biopharma has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GT Biopharma this week, compared to 0 articles on an average week.Search Interest4 people have searched for GTBP on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of GT Biopharma is held by insiders.Percentage Held by InstitutionsOnly 8.15% of the stock of GT Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GT Biopharma are expected to decrease in the coming year, from ($9.31) to ($10.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GT Biopharma is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GT Biopharma is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGT Biopharma has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About GT Biopharma Stock (NASDAQ:GTBP)GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Read More GTBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTBP Stock News HeadlinesMarch 27, 2024 | benzinga.comRecap: GT Biopharma Q4 EarningsMarch 26, 2024 | globenewswire.comGT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.February 25, 2024 | msn.comGT Biopharma (GTBP) Price Target Increased by 2900.00% to 153.00February 14, 2024 | finance.yahoo.comGTBP Feb 2024 2.500 callFebruary 2, 2024 | finance.yahoo.comGT Biopharma, Inc. (GTBP)February 2, 2024 | msn.comGT Biopharma Announces Reverse Stock Split UpdateFebruary 2, 2024 | benzinga.comGT Biopharma Stock (NASDAQ:GTBP), Short Interest ReportMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 1, 2024 | finance.yahoo.comGT Biopharma, Inc. Announces 1-for-30 Reverse Stock SplitDecember 14, 2023 | markets.businessinsider.comBuy Rating for GT Biopharma: High Efficacy and Expanded Potential in Oncology TherapeuticsDecember 6, 2023 | finance.yahoo.comLeading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of StockholdersDecember 4, 2023 | msn.comGT Biopharma submits IND to FDA for CD33+ leukemia therapyDecember 4, 2023 | finance.yahoo.comGT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ LeukemiaNovember 23, 2023 | markets.businessinsider.comGT Biopharma: Strong Q3 Performance and Promising Pipeline Progression Justify Buy RatingNovember 6, 2023 | finance.yahoo.comGT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNovember 1, 2023 | msn.comGT Biopharma GAAP EPS of -$0.06November 1, 2023 | finance.yahoo.comGT Biopharma Reports Third Quarter 2023 Financial ResultsAugust 24, 2023 | finance.yahoo.comGT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAugust 8, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on GT Biopharma (GTBP)August 7, 2023 | finanznachrichten.deGT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2023 Financial ResultsAugust 7, 2023 | finance.yahoo.comGT Biopharma Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comGT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023June 2, 2023 | msn.comHere's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock NowMay 19, 2023 | msn.comAll You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to BuyMay 18, 2023 | msn.comHC Wainwright & Co. Reiterates GT Biopharma (GTBP) Buy RecommendationMay 17, 2023 | msn.comEF Hutton Reiterates GT Biopharma (GTBP) Hold RecommendationSee More Headlines Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2021Today3/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CUSIPN/A CIK109657 Webwww.gtbiopharma.com Phone(415) 919-4040FaxN/AEmployees2Year Founded1965Price Target and Rating Average Stock Price Target$105.00 High Stock Price Target$150.00 Low Stock Price Target$60.00 Potential Upside/Downside+2,259.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($9.0090) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-125.05% Return on Assets-81.86% Debt Debt-to-Equity RatioN/A Current Ratio3.15 Quick Ratio3.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.84 per share Price / Book0.41Miscellaneous Outstanding Shares1,380,000Free Float1,241,000Market Cap$6.14 million OptionableOptionable Beta0.57 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Michael Martin Breen (Age 61)Interim CEO & Executive Chairman Comp: $1.09MMr. Manu Ohri (Age 69)CFO & Secretary Comp: $544.87kDr. Jeffrey S. Miller M.D.Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific AdvisorKey CompetitorsSonnet BioTherapeuticsNASDAQ:SONNOragenicsNYSE:OGENXenetic BiosciencesNASDAQ:XBIOHoth TherapeuticsNASDAQ:HOTHSoligenixNASDAQ:SNGXView All CompetitorsInsidersMichael Martin BreenBought 1,666 shares on 4/11/2023Total: $24,990.00 ($15.00/share)Manu OhriBought 1,666 shares on 4/6/2023Total: $24,990.00 ($15.00/share)View All Insider Transactions GTBP Stock Analysis - Frequently Asked Questions Should I buy or sell GT Biopharma stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GTBP shares. View GTBP analyst ratings or view top-rated stocks. What is GT Biopharma's stock price target for 2024? 2 Wall Street analysts have issued 12 month price targets for GT Biopharma's stock. Their GTBP share price targets range from $60.00 to $150.00. On average, they expect the company's stock price to reach $105.00 in the next twelve months. This suggests a possible upside of 2,259.6% from the stock's current price. View analysts price targets for GTBP or view top-rated stocks among Wall Street analysts. How have GTBP shares performed in 2024? GT Biopharma's stock was trading at $7.65 at the beginning of the year. Since then, GTBP stock has decreased by 41.8% and is now trading at $4.45. View the best growth stocks for 2024 here. Are investors shorting GT Biopharma? GT Biopharma saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 4,900 shares, a decline of 14.0% from the February 29th total of 5,700 shares. Based on an average trading volume of 12,600 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.4% of the company's stock are short sold. View GT Biopharma's Short Interest. When is GT Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our GTBP earnings forecast. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) announced its quarterly earnings data on Thursday, April, 15th. The company reported ($101.70) EPS for the quarter, missing the consensus estimate of ($1.20) by $100.50. When did GT Biopharma's stock split? GT Biopharma shares reverse split before market open on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GT Biopharma's major shareholders? GT Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Manu Ohri and Michael Martin Breen. View institutional ownership trends. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTBP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.